隶属于 foundation for national health & education of medical doctors
相关临床试验
154
28 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1769
进行中（未招募）
13
8.4%
已完成
65
42.2%
Enrolling By Invitation
6
3.9%
尚未招募
9
5.8%
招募中
50
32.5%
终止
2
1.3%
Unknown
9
5.8%
暂无批准数据
- Many patients with rheumatoid arthritis and other immune-mediated inflammatory diseases fail to meet treatment goals despite biologic therapy, giving rise to a "difficult-to-treat" population that requires holistic care. - Psychosocial distress, comorbidities, chronic pain syndromes, and system-related barriers — not just pharmacotherapeutic failure — drive poor outcomes in difficult-to-treat patients, according to viewpoint articles in Nature Reviews Rheumatology and Lancet Rheumatology. - Experts emphasize that rheumatologists must look beyond disease activity scores, incorporating multidisciplinary care, lifestyle medicine, and patient-centered communication to address the full complexity of these cases. - Leading rheumatologists call on organizations like the ACR and EULAR to expand clinical guidelines, fund research into non-pharmacologic therapies, and codify whole-person care models for this underserved population.
- New research in Pharmaceutics shows that alkaline bottled water can prematurely dissolve enteric coatings on medications within minutes, potentially altering drug release and absorption. - Apple juice and other acidic beverages slowed drug release, while tap water maintained coating integrity for the majority of tested formulations. - Of 103 enteric-coated drug labels reviewed, only nine provided specific guidance on which beverage to use, highlighting a critical gap in patient instructions. - Researchers recommend that patients take enteric-coated medications with plain tap water and consult a pharmacist before opening capsules or mixing with other liquids.
- Algernon NeuroScience appoints Dr. Sándor Nardai to lead a groundbreaking Phase 2a clinical trial investigating DMT as a potential stroke recovery treatment, set to begin in Q3 2025. - The 40-patient randomized trial will evaluate DMT's safety profile and monitor key indicators including lesion volume, motor function, and cognitive improvements in stroke patients. - Preclinical studies showed promising results with sub-hallucinogenic DMT doses, demonstrating near-complete motor function recovery and reduced infarct volumes in rat models.
